Fesoterodine in randomised clinical trials: an updated systematic clinical review of efficacy and safety

[1] Haylen BT(2010)An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction Int Urogynecol J Pelvic Floor Dysfunct 21 5-26

[2] de Ridder D(2011)Validity and reliability of patient selected goals as an outcome measure in overactive bladder Int Urogynecol J Pelvic Floor Dysfunct 22 841-847

[3] Freeman RM(2006)Population based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: the results of the EPIC study Eur Urol 50 1306-1314

[4] Cartwright R(2003)Prevalence and burden of overactive bladder in the United States World J Urol 20 327-336

[5] Srikrishna S(2003)Impact of urinary incontinence and overactive bladder on quality of life Eur Urol 43 535-538

[6] Cardozo L(2009)Efficacy and tolerability of fesoterodine in women with overactive bladder Int Urogynecol J Pelvic Floor Dysfunct 20 827-835

[7] Robinson D(2011)Women's perspective of botulinum toxin treatment for overactive bladder symptoms Int Urogynecol J Pelvic Floor Dysfunct 22 425-431

[8] Irwin DE(2011)Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity Int Urogynecol J Pelvic Floor Dysfunct 22 907-917

[9] Milsom I(2010)Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status Int Urogynecol J Pelvic Floor Dysfunct 21 847-854

[10] Hunskaar S(2008)Fesoterodine Dose Response in Subjects with Overactive Bladder Syndrome Fem Urol 71 839-843

[1] Haylen BT(2010)An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction Int Urogynecol J Pelvic Floor Dysfunct 21 5-26

[2] de Ridder D(2011)Validity and reliability of patient selected goals as an outcome measure in overactive bladder Int Urogynecol J Pelvic Floor Dysfunct 22 841-847

[3] Freeman RM(2006)Population based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: the results of the EPIC study Eur Urol 50 1306-1314

[4] Cartwright R(2003)Prevalence and burden of overactive bladder in the United States World J Urol 20 327-336

[5] Srikrishna S(2003)Impact of urinary incontinence and overactive bladder on quality of life Eur Urol 43 535-538

[6] Cardozo L(2009)Efficacy and tolerability of fesoterodine in women with overactive bladder Int Urogynecol J Pelvic Floor Dysfunct 20 827-835

[7] Robinson D(2011)Women's perspective of botulinum toxin treatment for overactive bladder symptoms Int Urogynecol J Pelvic Floor Dysfunct 22 425-431

[8] Irwin DE(2011)Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity Int Urogynecol J Pelvic Floor Dysfunct 22 907-917

[9] Milsom I(2010)Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status Int Urogynecol J Pelvic Floor Dysfunct 21 847-854

[10] Hunskaar S(2008)Fesoterodine Dose Response in Subjects with Overactive Bladder Syndrome Fem Urol 71 839-843